The administration of figitumumab, an anti-IGF-1R mAb, has been associated with objective responses in Ewing sarcoma patients [21], whereas R1507, another IGF-1R antagonist mAb, had mixed results in two studies [22, 23]. This evidence concerns the gene IGF1R and Ewing sarcoma.